Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2025
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET233
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 11, 2025
Lead Product(s) : MET233
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET097
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : MET097
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2025
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : BofA Securities
Deal Size : $316.2 million
Deal Type : Public Offering
Metsera Closes IPO, Underwriters’ Option Fully Exercised
Details : The proceeds from the offering will used to fund the clinical development of MET097, which is being evalauted for the treatment of obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 05, 2025
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : BofA Securities
Deal Size : $316.2 million
Deal Type : Public Offering
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : BofA Securities
Deal Size : $275.0 million
Deal Type : Public Offering
Metsera Announces Pricing of Initial Public Offering
Details : The proceeds from the offering will used to fund the clinical development of MET097, which is being evalauted for the treatment of obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 30, 2025
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : BofA Securities
Deal Size : $275.0 million
Deal Type : Public Offering
Lead Product(s) : MET-097i
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Metsera Announces Positive Phase 2a Data for GLP-1 Agonist MET-097i
Details : MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA), being investigated for obesity and overweight.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : MET-097i
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : MET097
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity
Details : ET-097i is an ultra-long-acting injectable amylin analog, fully biased GLP-1 receptor agonist, being investigated in patients with obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Wellington Management
Deal Size : $215.0 million
Deal Type : Series B Financing
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
Details : The proceeds will be used to further advance its portfolio of NuSH analog peptides, including MET-097i, a novel, fully-biased, potential once-monthly subcutaneously injectable GLP-1 RA.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Wellington Management
Deal Size : $215.0 million
Deal Type : Series B Financing